POLYMEDNSEPoly Medicure Limited· PharmaceuticalsMinimalNeutral
Announced Thu, 8 May · 17:15 IST

Poly Medicure Limited has informed the Exchange about Copy of Newspaper Publication

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Poly Medicure Limited has submitted copies of newspaper advertisements published in Financial Express and Jansatta on May 8, 2025, containing its audited financial results for Q4 FY25 and full year ended March 31, 2025. On a standalone basis, total income from operations rose about 24% year-on-year to Rs 1,691.57 crore, while profit after tax grew roughly 32% to Rs 331.33 crore for the full year. For Q4 alone, standalone revenue was Rs 444.92 crore and PAT was Rs 86.66 crore, both up from the year-ago quarter. Consolidated FY25 revenue stood at Rs 1,758.96 crore with PAT of Rs 338.56 crore, and basic EPS improved to Rs 33.40 (standalone) and Rs 34.13 (consolidated), up from Rs 26.24 and Rs 26.92 respectively a year earlier.

Likely market impact

The filing is a routine compliance disclosure under SEBI listing rules, so it does not carry new information beyond what was already announced. However, the strong double-digit growth in revenue, profit, and EPS year-on-year is a positive signal for shareholders and likely supports a constructive view on the stock's earnings trajectory.